Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Pre-radiation temozolomide.
Pre-radiation temozolomide · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| Pre-radiation temozolomide. | DRUG | Patients will receive 2 cycles of pre-radiation temozolomide (200mg/m\^2). Cycles are 28-days in length. Participants will take temozolomide on days 1-5 of the 28-day cycle. |
Pre-radiation temozolomide is an investigational small molecule being studied for the treatment of high grade gliomas, including glioblastoma, astrocytoma, and oligodendroglioma. It is administered as chemotherapy before radiation therapy in patients with newly diagnosed high grade glioma. The drug is currently in Phase 2 clinical development.
Pre-radiation temozolomide is being developed by The Cooper Companies, Inc., which trades under the ticker COO. The company is conducting a Phase 2 clinical trial to evaluate the drug in patients with newly diagnosed high grade glioma.
Pre-radiation temozolomide is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is designed to evaluate the drug's safety and efficacy in patients with high grade gliomas.
Pre-radiation temozolomide is being studied in one Phase 2 clinical trial with the identifier NCT07439172, titled 'Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.' The trial is not yet recruiting and plans to enroll approximately 70 patients with high grade gliomas, glioblastoma, astrocytoma, or oligodendroglioma.
Pre-radiation temozolomide is a formulation of temozolomide that is administered before radiation therapy. The drug name indicates the timing of administration relative to radiation, and it is being studied specifically for use in patients with newly diagnosed high grade glioma.